

PATENT
Attorney Docket No. NIH-05080

9/K.T.
7/25

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Geoff J. Clark *et al.*

Serial No.: 09/873,546

Group No.:

Filed: 06/04/01

Examiner:

Entitled:

**Compositions And Methods Related To The
Rig Tumor Suppressor Gene And Protein**

I.D.


TECH CENTER 1600/2900

JUL 23 2002

RECEIVED

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

<p align="center">CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on July 11, 2002.</p> <p align="right">By:  James R. Davenport</p>

Sir or Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

The following patents are referred to in the body of the specification:

- U.S. Patent No. 4,683,195;
- U.S. Patent No. 4,683,202;
- U.S. Patent No. 4,965,188;

The following printed publications are referred to in the body of the specification:

- ATCC CRL No. 1573;
- ATCC CRL No. 1651;
- ATCC CRL No. 1658;
- ATCC CRL No. 1598;
- ATCC Catalog No. 3363561;

- Amado and Chen (1999) "Lentiviral Vectors - the Promise of Gene Therapy Within Reach?" *Science* 285:674-676;
- Anderson and Young, Quantitative Filter Hybridization, in *Nucleic Acid Hybridization* [1985];
- Andrejauskas and Moroni (1989) "Reversible abrogation of IL-3 dependence by an inducible H-*ras* oncogene," *EMBO J.* 8:2575-2581;
- Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology*, Vols. I-IV, John Wiley & Sons, Inc., New York [1994];
- Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology*, Ch. 11, John Wiley & Sons, Inc., New York [1994];
- Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology*, Vol. 1, pages 4.9.1-4.9.16, John Wiley & Sons, Inc., New York [1994];
- Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology*, Section 15.4, "Enzymatic Amplification of RNA by PCR," John Wiley & Sons, Inc., New York [1994];
- Ausubel *et al.* (eds.) (*Current Protocols in Molecular Biology*, Section 10.8, "Immunoblotting and Immunodetection," John Wiley & Sons, Inc., New York [1994];
- Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology*, Vol. 4, Section A.3F, "Techniques for Mammalian Cell Tissue Culture," John Wiley & Sons, Inc., New York [1994];
- Bar-Sagi (2001) "A Ras by Any Other Name," *Mol. Cell Biol.* 21:1441-1443;
- Bar-Sagi and Feramisco (1985) "Microinjection of the *ras* Oncogene Protein into PC12 Cells Induces Morphological Differentiation," *Cell* 42:841-848;
- Barbacid (1987) "*ras* Genes," *Annu. Rev. Biochem.* 56:779-827;
- Bildirici *et al.* (2000) "Transfection of cells by immunoporation," *Nature* 405:298;
- Bos (1989) "*ras* Oncogenes in Human Cancer: A Review," *Cancer Res.* 49:4682-4689;
- Boshart *et al.* (1985) "A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus," *Cell* 41:521;

- Burton *et al.* (1999) "Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein," Proc. Natl. Acad. Sci. USA 96(22):12725-12730;
- Campbell *et al.* (1998) "Increasing complexity of Ras signaling," Oncogene 17:1395-1413;
- Cavazzana-Calvo *et al.* (2000) "Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease," Science 288:669-672;
- Cepko *et al.* (1984) "Construction and Applications of a Highly Transmissible Murine Retrovirus Shuttle Vector," Cell 37:1053-1062;
- Chen and Faller (1995) "Injection of p21^{ras}-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2," Oncogene 11:1487-1498;
- Chi *et al.* (1999) "Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells," Oncogene 18:2281-2290;
- Clark *et al.* (1993) "Differential antagonism of Ras biological activity by catalytic and Src homology domains of Ras GTPase activation protein," Proc. Natl. Acad. Sci. USA 90:4887-4891;
- Clark *et al.* (1997) "The Ras-related Protein Rheb Is Farnesylated and Antagonizes Ras Signaling and Transformation," J. Biol. Chem. 272:10608-10615;
- Clark *et al.* (1995) "Biological Assays for Ras Transformation," Methods Enzymol. 255:395-412;
- Clark and Der in *GTPases in Biology*, eds. Dickey and Birmbauer, Springer-Verlag London Ltd., pp. 259-287, 1993;
- Cohen *et al.* (1972) "Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation of *Escherichia coli* by R-Factor DNA," Proc. Natl. Acad. Sci. USA 69: 2110-2114;
- Cole *et al.* (1985) "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96;

- Connelly *et al.* (1998) "Sustained Phenotypic Correction of Murine Hemophilia A by In Vivo Gene Therapy," *Blood* 91:3273-3281;
- Connelly *et al.* (1996) "Complete Short-Term Correction of Canine Hemophilia B by In Vivo Gene Therapy," *Blood* 88:3846-3853;
- Coombs, *Dictionary of Biotechnology*, Stockton Press, New York NY [1994];
- Crowther, "Enzyme-Linked Immunosorbent Assay (ELISA)," in *Molecular Biomethods Handbook*, Rapley *et al.* [eds.], pp. 595-617, Humana Press, Inc., Totowa, NJ [1998];
- Dijkema *et al.* (1985) "Cloning and expression of the chromosomal immune interferon gene of the rat," *EMBO J.* 4:761;
- Fabian *et al.* (1994) "A single amino acid change in Raf-1 inhibits Ras binding and alter Raf-1 function," *Proc. Natl. Acad. Sci. USA* 91:5982-5986;
- Fiordalisi *et al.* (2001) "Mammalian Expression Vectors for Ras Family Proteins: Generation and Use of Expression Constructs to Analyze Ras Family Function," *Methods Enzymol.* 332:3-36;
- GenBank Accession No. NP_004666;
- GenBank Accession No. AC006538;
- GenBank Accession No. AAD13119;
- GenBank Accession No. AI497811;
- GenBank Accession No. P10301;
- GenBank Accession No. P10113;
- GenBank Accession No. P01112;
- GenBank Accession No. Q15382;
- GenBank Accession No. TVHUAA;
- GenBank Accession No. XP_007223;
- Gorman *et al.* (1982) "The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection," *Proc. Natl. Acad. Sci. USA* 79:6777;
- Graham and van der Eb (1973) "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA," *Virology* 52:456;

- Hanahan (1983) "Studies on Transformation of *Escherichia coli* with Plasmids," Mol. Biol. 166:557-580;
- Harlow and Lane (eds.) *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press [1988];
- Hofmann *et al.* (1996) "Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette," Proc. Natl. Acad. Sci. USA 93(11):5185-5190;
- Huber and Cordingley (1988) "Expression and phenotypic alterations caused by an inducible transforming *ras* oncogene introduced into rat liver epithelial cells," Oncogene 3:245-256;
- Joneson and Bar-Sagi (1999) "Suppression of Ras-Induced Apoptosis by the Rac GTPase," Mol. Cell. Biol. 19:5892-5901;
- Katz and McCormick (1997) "Signal transduction from multiple Ras effectors," Curr. Opin. Genet. Dev. 7:75-79;
- Kauffmann-Zeh *et al.* (1997) "Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB," Nature 385:544-548;
- Kay *et al.* (2000) "Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector," Nature Genetics 24:257-261;
- Kim *et al.* (1990) "Use of the human elongation factor 1 α promoter as a versatile and efficient expression system," Gene 91:217;
- Köhler and Milstein (1975) "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion," Nature 256:495-497;
- Kozbor *et al.* (1983) "The production of monoclonal antibodies from human lymphocytes," Immunol. Today 4:72;
- Kwok *et al.* (1986) "Retroviral transfer of genes into canine hemopoietic progenitor cells in culture: A model for human gene therapy," Proc. Natl. Acad. Sci. USA 83:4552-4555;
- Laurino *et al.* (1999) "Monoclonal Antibodies, Antigens and Molecular Diagnostics: A Practical Overview," Ann. Clin. Lab Sci. 29(3):158-166;

- Lowy and Willumsen (1993) "Function and Regulation of Ras," *Annu. Rev. Biochem.* 62:851-891;
- McCormick (1993) "How receptors turn Ras on," *Nature* 363:15;
- Mahato *et al.* (1999) "Pharmaceutical Perspectives of Nonviral Gene Therapy," *Adv. Genet.* 41:95-156;
- Malumbres and Pellicer (1998) "Ras Pathways to Cell Cycle Control and Cell Transformation," *Front Biosci* 3:d887-d912;
- Maniatis *et al.* (1987) "Regulation of Inducible and Tissue-Specific Gene Expression," *Science* 236:1237;
- Maniatis *et al.* (eds.), *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, NY, 1982;
- Marshall (1994) "MAP kinase kinase kinase, MAP kinase kinase and MAP kinase," *Curr. Opin. Genet. Dev.* 4:82-89;
- Mayo *et al.* (1997) "Requirement of Nf- κ B Activation to Suppress p53-Independent Apoptosis Induced by Oncogenic Ras," *Science* 278:1812-1815;
- Mizushima and Nagata (1990) "pEF-BOS, a powerful mammalian expression vector," *Nuc. Acids. Res.* 18:5322;
- Morgenstern *et al.* (1990) "Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line," *Nucl. Acids Res.* 18:3587-3596;
- Mulcahy *et al.* (1985) "Requirement for *ras* proto-oncogene function during serum-stimulated growth of NIH 3T3 cells," *Nature* 313:241-243;
- Mullis *et al.* (eds.) "RT-PCR and Gene Expression," in *PCR - The Polymerase Chain Reaction*, Chapter 24, Birkhauser Publishers, Cambridge, MA (1994);
- Mullis *et al.* (1986) "Specific Enzymatic Amplification of DNA In Vitro: The Polymerase Chain Reaction," *Cold Spring Harbor Symposia*, Vol. LI, pp 263-273;
- Feig (1999) "Tools of the trade: use of dominant-inhibitory mutants of Ras-family GTPases," *Nature Cell Biol.* 1:E25-E27;
- Nolan and Shatzman (1998) "Expression vectors and delivery systems," *Curr. Opin. Biotechnol.* 9:447-450;

- Ochieng *et al.* (1991) "Increased Invasive, Chemotactic and Locomotive Abilities of c-Ha-ras-Transformed Human Breast Epithelial Cells," *Invasion Metastasis* 11:38-47;
- Paterson *et al.* (1987) "Activated N-ras Controls the Transformed Phenotype of HT1080 Fibrosarcoma Cells," *Cell* 51:803-812;
- Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, New York (1989), pp 16.7-16.8;
- Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, New York (1989), pp.16.6-16.7;
- Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, New York (1989), at pp.16.9-16.15;
- Sambrook *et al.* (eds.), *Molecular Cloning*, Cold Spring Harbor Laboratory Press [1989];
- Serrano *et al.* (1997) "Oncogenic *ras* Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16^{INK4a}," *Cell* 88:593-602;
- Shirasawa *et al.* (1993) "Altered Growth of Human Colon Cancer Cell Lines Disrupted at Activated Ki-ras," *Science* 260:85-88;
- Takiguchi *et al.* (1992) "NIH3T3 transfectant containing human K-ras oncogene shows enhanced metastatic activity after *in vivo* tumor growth or co-culture with fibroblasts," *Clin. Exp. Metastasis* 10:351-360;
- Trahey *et al.* (1987) "Biochemical and Biological Properties of the Human N-ras p21 Protein," *Mol. Cell Biol.* 7:541-544;
- Uetsuki *et al.* (1989) "Isolation and Characterization of the Human Chromosomal Gene for Polypeptide Chain Elongation Factor-1 α ," *J. Biol. Chem.* 264:5791;
- Voss *et al.* (1986) "The roles of enhancers in the regulation of cell-type-specific transcriptional control," *Trends Biochem. Sci.* 11:287;
- Walker (ed.), *The Protein Protocols Handbook*, Part III, "Blotting and Detection Methods," Humana Press, Totowa, New Jersey [1996];


- Wang *et al.* (1991) "Cell surface receptor for ecotropic murine retroviruses as a basic amino-acid transporter," Nature 352:729-731;
- Yu *et al.* (1999) "*NOEY2* (ARHI) , an imprinted putative tumor suppressor gene in ovarian and breast carcinomas," Proc. Natl. Acad. Sci. USA 96:214-219;
- Yuspa *et al.* (1985) "Keratinocytes blocked in phorbol ester-responsive early stage of terminal differentiation by sarcoma viruses," Nature 314:459-462; and
- Zhang (1999) "Development and application of adenoviral vectors for gene therapy of cancer," Cancer Gene Ther. 6(2):113-138.

Applicants have become aware of the following printed publications which may be material to the examination of this application:

- Hengartner (2000) "The biochemistry of apoptosis," Nature 407:770;
- Krammer (2000) "CD95's deadly mission in the immune system," Nature 407:789;
- Nicholson (2000) "From bench to clinic with apoptosis-based therapeutic agents," Nature 407:810-816;
- Vos *et al.* (2000) "Ras Uses the Novel Tumor Suppressor RASSF1 as an Effector to Mediate Apoptosis," J. Biol. Chem. 275:35669;
- Watsuji *et al.* (1997) "Controlled Gene Expression with a Reverse Tetracycline-Regulated Retroviral Vector (RTRV) System," Biochem. Biophys. Res. Comm. 234:769; and
- GenBank Accession No. AAD03164.

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: July 11, 2002



Judith S.H. Hom
Registration No. 44,772

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415.904.6500



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Geoff J. Clark *et al.*

Serial No.: 09/873,546

Group No.:

Filed: 06/04/2001

Examiner:

Entitled: **Compositions And Methods Related To The Rig Tumor
Suppressor Gene And Protein**

TECH CENTER 1600/2900

JUL 23 2002

RECEIVED

**INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL**

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Dated: July 11, 2002

By:


James R. Davenport

Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. **An originally executed duplicate of this transmittal is enclosed for this purpose.**

Dated: July 11, 2002


Judith S.H. Hom

Registration No. 44,772

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415/904-6500